Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Psoriasis is a common, chronic inflammatory disease characterized by sustained inflammation and hyperproliferation of epidermal keratinocytes. With the establishment of the interleukin (IL)-17/IL-23 pathway as a principal player in the etiopathogenesis of psoriasis, and the subsequent development of anti-IL-17/IL-23 biologics, targeted treatment for psoriasis has significantly improved within the past decade. Currently, 4 IL-17 inhibitors are approved for the treatment of moderate to severe plaque psoriasis in adults-secukinumab, ixekizumab, brodalumab and bimekizumab-all of which are monoclonal antibodies. In this scoping review article, we present the current literature on sonelokimab, a novel anti-IL-17A/F nanobody for the treatment of moderate to severe psoriasis.

TidsskriftDrugs of the Future
Udgave nummer8
Sider (fra-til)567-573
Antal sider7
StatusUdgivet - aug. 2022

ID: 317739663